2023
Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis
Heuts S, Gabrio A, Veenstra L, Maesen B, Kats S, Maessen J, Walton A, Nanayakkara S, Lansky A, van 't Hof A, Vriesendorp P. Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis. Heart 2023, 110: 757-765. PMID: 37996242, DOI: 10.1136/heartjnl-2023-323359.Peer-Reviewed Original ResearchTranscatheter aortic valve implantationCerebral embolic protectionAbsolute risk differenceAortic valve implantationRelative riskTAVI patientsValve implantationSystematic reviewCerebral embolic protection devicesMedian relative riskEmbolic protection devicesMultiple sensitivity analysesEmbolic protectionPrimary outcomeFuture trialsStandard treatmentStroke reductionBaseline riskRisk differenceElectronic databasesExpert consensusNew-generation devicesSecondary analysisStrokeRelevant reductionCerebral embolic protection during transcatheter heart interventions.
Jimenez Diaz V, Kapadia S, Linke A, Mylotte D, Lansky A, Grube E, Settergren M, Puri R. Cerebral embolic protection during transcatheter heart interventions. EuroIntervention 2023, 19: 549-570. PMID: 37720969, PMCID: PMC10495748, DOI: 10.4244/eij-d-23-00166.Peer-Reviewed Original ResearchConceptsCerebral embolic protection devicesTranscatheter aortic valve replacementNew cerebral lesionsMajority of patientsCerebral lesionsTransfemoral transcatheter aortic valve replacementHeart interventionsCerebral embolic protectionAortic valve replacementEmbolic protection devicesBrain imaging studiesPrimary endpointDevastating complicationPeriprocedural strokeValve replacementEmbolic protectionEmbolic showerApparent strokeCerebral embolisationTranscatheter proceduresSpecific trialsImaging studiesStrokePatientsLesions
2020
Chapter 41 Embolic protection devices for stroke prevention during cardiac interventions
Ghare M, Zhou S, Tirziu D, Lansky A. Chapter 41 Embolic protection devices for stroke prevention during cardiac interventions. 2020, 941-960. DOI: 10.1016/b978-0-12-813704-8.00041-3.Peer-Reviewed Original ResearchTranscatheter aortic valve implantationAortic stenosisSevere symptomatic aortic stenosisSurgical aortic valve replacementSymptomatic aortic stenosisAortic valve replacementHigh-risk patientsPrevention of strokeAortic valve implantationEmbolic protection devicesNeurologic eventsStroke preventionDevastating complicationIntermediate riskNeurologic injuryValve implantationValve replacementAdjunctive pharmacotherapyStroke rateCurrent evidenceTranscatheter proceduresCardiac interventionsPatientsStrokePrevention
2018
TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy.
Lansky A, Ghare MI, Tchétché D, Baumbach A. TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy. EuroIntervention 2018, 14: ab53-ab63. PMID: 30158096, DOI: 10.4244/eij-d-18-00454.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic stenosisAdjunctive pharmacotherapySevere symptomatic aortic stenosisIntermediate-risk patientsSymptomatic aortic stenosisHigh-risk patientsAortic valve implantationSurgical valve replacementEvidence of neuroprotectionNeurologic eventsDevastating complicationNeurologic injuryValve implantationValve replacementCurrent evidenceNeuroprotectionPharmacotherapyPatientsPreferred methodComplicationsStenosisInjuryStrokeIncidence
2015
The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacement
Baumbach A, Pietras C, Lansky A. The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacement. Expert Review Of Medical Devices 2015, 12: 649-651. PMID: 26364995, DOI: 10.1586/17434440.2015.1086642.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic valve implantationValve implantationTranscatheter aortic valve replacementIschemic cerebral eventsAortic valve replacementPrevention of strokeCerebral embolizationEmbolic strokeCerebral eventsEmbolic eventsValve replacementEmbolic lesionsClinical studiesNeurocognitive impairmentNeurocognitive functionMemory lossVessel ostiumStrokeBrain circulationImplantationEmbolizationOstiumLesionsIncidence
2004
Comparison of frequency of hemorrhagic stroke in patients <75 years versus ≥75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions
Iakovou I, Dangas G, Mintz GS, Mehran R, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Comparison of frequency of hemorrhagic stroke in patients <75 years versus ≥75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. The American Journal Of Cardiology 2004, 93: 346-349. PMID: 14759388, DOI: 10.1016/j.amjcard.2003.10.018.Peer-Reviewed Original Research
2003
Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥75 years of age versus those <75 years of age
Iakovou I, Dangas G, Mehran R, Mintz GS, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥75 years of age versus those <75 years of age. The American Journal Of Cardiology 2003, 92: 1083-1086. PMID: 14583360, DOI: 10.1016/j.amjcard.2003.07.007.Peer-Reviewed Original Research